Tcw Group Inc Allovir, Inc. Transaction History
Tcw Group Inc
- $11.2 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding ALVR
# of Institutions
72Shares Held
45MCall Options Held
201KPut Options Held
3.1K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$6.32 Million0.29% of portfolio
-
Octagon Capital Advisors LP New York, NY9.8MShares$5.49 Million1.63% of portfolio
-
Siren, L.L.C. New York, NY6.6MShares$3.69 Million0.27% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.3MShares$1.85 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$1.48 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $52.1M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...